Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
(NASDAQ: CMPX) Delayed: 2.07 -0.03 (1.43%)
Previous Close $2.10    52 Week High $ 
Open $2.04    52 Week Low $ 
Day High $2.11    P/E N/A 
Day Low $2.04    EPS $ 
Volume 2,632,067